All Relations between Tuberous Sclerosis and mtor

Publication Sentence Publish Date Extraction Date Species
Yasutaka Okita, Maiko Yoshimura, Yoshinori Katada, Yukihiko Saeki, Shiro Ohshim. A Mechanistic Target of Rapamycin (mTOR) Inhibitor, Everolimus Safely Ameliorated Lupus Nephritis in a Patient Complicated with Tuberous Sclerosis. Modern rheumatology case reports. 2022-05-05. PMID:35512453. a mechanistic target of rapamycin (mtor) inhibitor, everolimus safely ameliorated lupus nephritis in a patient complicated with tuberous sclerosis. 2022-05-05 2023-08-13 Not clear
Yu-Ting Lin, Chia-Ling Yu, Yu-Kang Tu, Ching-Chi Ch. Efficacy and Safety of Topical Mechanistic Target of Rapamycin Inhibitors for Facial Angiofibromas in Patients with Tuberous Sclerosis Complex: A Systematic Review and Network Meta-Analysis. Biomedicines. vol 10. issue 4. 2022-04-23. PMID:35453576. previous studies have suggested that the topical mechanistic target of rapamycin (mtor) inhibitors may be effective in treating facial angiofibromas in patients with tuberous sclerosis complex (tsc). 2022-04-23 2023-08-13 Not clear
Cong Luo, Wen-Rui Ye, Wei Shi, Ping Yin, Chen Chen, Yun-Bo He, Min-Feng Chen, Xiong-Bin Zu, Yi Ca. Perfect match: mTOR inhibitors and tuberous sclerosis complex. Orphanet journal of rare diseases. vol 17. issue 1. 2022-03-05. PMID:35246210. perfect match: mtor inhibitors and tuberous sclerosis complex. 2022-03-05 2023-08-13 human
Wenda Wang, Zhan Wang, Yang Zhao, Xu Wang, Hanzhong Li, Yushi Zhan. Analysis of serum lipid parameters predicting lipid metabolic disorders in TSC-AML patients with treatment of mTOR inhibitors. Journal of clinical pharmacy and therapeutics. 2022-03-01. PMID:35229896. patients with tuberous sclerosis complex (tsc) demonstrate disrupted lipid homeostasis before and during treatment with mammalian target of rapamycin (mtor) inhibitor. 2022-03-01 2023-08-13 Not clear
Lena H Nguyen, Steven C Leiser, Dekun Song, Daniela Brunner, Steven L Roberds, Michael Wong, Angelique Borde. Inhibition of MEK-ERK signaling reduces seizures in two mouse models of tuberous sclerosis complex. Epilepsy research. vol 181. 2022-02-26. PMID:35219048. tuberous sclerosis complex (tsc) is a monogenic disorder characterized by hyperactivation of the mtor signaling pathway and developmental brain malformations leading to intractable epilepsy. 2022-02-26 2023-08-13 mouse
Jennifer M Gibson, Cleone P Howland, Chongyu Ren, Cyrena Howland, Alexandra Vernino, Peter T Tsa. A critical period for development of cerebellar-mediated autism-relevant social behavior. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2022-02-22. PMID:35190469. in this study, we identify a critical period for the development of asd-relevant behaviors in a cerebellar male mouse model of tuberous sclerosis complex (tsc), by using the mechanistic target of rapamycin (mtor) inhibitor, rapamycin, to pharmacologically inhibit dysregulated downstream signaling. 2022-02-22 2023-08-13 mouse
Andrew R Tee, Brendan D Manning, Philippe P Roux, Lewis C Cantley, John Bleni. Tuberous Sclerosis Complex Gene Products, Tuberin and Hamartin, Control mTOR Signaling by Acting as a GTPase-Activating Protein Complex toward Rheb. Current biology : CB. vol 32. issue 3. 2022-02-08. PMID:35134350. tuberous sclerosis complex gene products, tuberin and hamartin, control mtor signaling by acting as a gtpase-activating protein complex toward rheb. 2022-02-08 2023-08-13 Not clear
Pedram Argani, Rohit Mehr. Renal cell carcinoma associated with tuberous sclerosis complex (TSC)/mammalian target of rapamycin (MTOR) genetic alterations. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2022-01-20. PMID:35046523. renal cell carcinoma associated with tuberous sclerosis complex (tsc)/mammalian target of rapamycin (mtor) genetic alterations. 2022-01-20 2023-08-13 Not clear
Victoria-Elisabeth Gruber, Mark J Luinenburg, Katrin Colleselli, Verena Endmayr, Jasper J Anink, Till S Zimmer, Floor Jansen, Peter Gosselaar, Roland Coras, Theresa Scholl, Ingmar Blumcke, José Pimentel, Johannes A Hainfellner, Romana Höftberger, Karl Rössler, Martha Feucht, Jackelien van Scheppingen, Eleonora Aronica, Angelika Mühlebne. Increased expression of complement components in tuberous sclerosis complex and focal cortical dysplasia type 2B brain lesions. Epilepsia. 2021-12-14. PMID:34904712. increasing evidence supports the contribution of inflammatory mechanisms to the neurological manifestations of epileptogenic developmental pathologies linked to mammalian target of rapamycin (mtor) pathway dysregulation (mtoropathies), such as tuberous sclerosis complex (tsc) and focal cortical dysplasia (fcd). 2021-12-14 2023-08-13 Not clear
Saber Tadros, Aleksei Kondrashov, Sriya Namagiri, Ashis Chowdhury, Yeshavanth Kumar Banasavadi-Siddegowda, Abhik Ray-Chaudhur. Pathological Features of Tumors of the Nervous System in Hereditary Cancer Predisposition Syndromes: A Review. Neurosurgery. vol 89. issue 3. 2021-11-25. PMID:33693933. understanding the signaling pathway alteration of mammalian target of rapamycin (mtor) in tuberous sclerosis helped introducing mtor inhibitors as a prophylactic treatment in these patients. 2021-11-25 2023-08-13 Not clear
Felipe I Chodraui, Camila Araújo B Garcia, Niele D Mendes, Marcelo V Santos, Pâmela S Beggiora, Stephanya C Silva, Thiago L Teixeira, Luiza da Silva Lopes, Fabiano P Saggioro, Luciano Neder, Hélio R Machad. Phosphorylation of S6 Protein as a Potential Biomarker in Surgically Treated Refractory Epilepsy. Developmental neuroscience. vol 42. issue 5-6. 2021-11-16. PMID:33706310. the tuberous sclerosis complex (tsc), focal cortical dysplasia iib (fcd iib), and hemimegalencephaly (hme) exhibit similar molecular features that are dependent on the hyperactivation of the mtor pathway. 2021-11-16 2023-08-13 Not clear
Elhusseiny Mohamed Mahmoud Abdelwahab, Judit Bovari-Biri, Gabor Smuk, Tunde Harko, Janos Fillinger, Judit Moldvay, Vera P Krymskaya, Judit E Pongrac. Normalization of Enzyme Expression and Activity Regulating Vitamin A Metabolism Increases RAR-Beta Expression and Reduces Cellular Migration and Proliferation in Diseases Caused by Tuberous Sclerosis Gene Mutations. Frontiers in oncology. vol 11. 2021-11-12. PMID:34178631. mutation in a tuberous sclerosis gene (tsc1 or 2) leads to continuous activation of the mammalian target of rapamycin (mtor). 2021-11-12 2023-08-13 Not clear
Elin Vinsland, Pranetha Baskaran, Simeon R Mihaylov, Carl Hobbs, Hannah Wood, Ihssane Bouybayoune, Kriti Shah, Corinne Houart, Andrew R Tee, Jernej Murn, Cathy Fernandes, Joseph M Batema. The zinc finger/RING domain protein Unkempt regulates cognitive flexibility. Scientific reports. vol 11. issue 1. 2021-11-12. PMID:34381067. activation of mtor signaling causes diseases with severe neurological manifestations, such as tuberous sclerosis complex and focal cortical dysplasia. 2021-11-12 2023-08-13 mouse
Michael Won. mTOR as a potential treatment target for epilepsy. Future neurology. vol 7. issue 5. 2021-11-10. PMID:23620711. mtor inhibitors can suppress seizures and prevent epilepsy in animal models of certain genetic epilepsies, such as tuberous sclerosis complex. 2021-11-10 2023-08-12 Not clear
Michael Won. mTOR as a potential treatment target for epilepsy. Future neurology. vol 7. issue 5. 2021-11-10. PMID:23620711. some clinical data suggest that mtor inhibitors decrease seizures in tuberous sclerosis complex patients, but controlled trials are lacking and no clinical data on potential anti-epileptogenic actions exist. 2021-11-10 2023-08-12 Not clear
Cormac McCarthy, Nishant Gupta, Simon R Johnson, Jane J Yu, Francis X McCormac. Lymphangioleiomyomatosis: pathogenesis, clinical features, diagnosis, and management. The Lancet. Respiratory medicine. vol 9. issue 11. 2021-11-08. PMID:34461049. the invading cell in lam arises from an unknown source and harbours mutations in tuberous sclerosis complex (tsc) genes that result in constitutive activation of the mechanistic target of rapamycin (mtor) pathway, dysregulated cellular proliferation, and a programme of frustrated lymphangiogenesis, culminating in disordered lung remodelling and respiratory failure. 2021-11-08 2023-08-13 Not clear
Karen Agricola, Gabrielle Stires, Darcy A Krueger, Jamie K Capal, David N Franz, David M Ritte. Diabetes in Individuals With Tuberous Sclerosis Complex Treated With mTOR Inhibitors. Pediatric neurology. vol 120. 2021-11-05. PMID:33962348. diabetes in individuals with tuberous sclerosis complex treated with mtor inhibitors. 2021-11-05 2023-08-13 Not clear
Sophie M Peeters, Yagmur Muftuoglu, Brian Na, David J Daniels, Anthony C Wan. Pediatric Gliomas: Molecular Landscape and Emerging Targets. Neurosurgery clinics of North America. vol 32. issue 2. 2021-10-28. PMID:33781501. promising targeted therapies include mtor inhibitors for subependymal giant cell astrocytomas in tuberous sclerosis, braf and mek inhibitors mainly for low-grade gliomas, and mek inhibitors for nf1-deficient braf:kiaa fusion tumors. 2021-10-28 2023-08-13 Not clear
Ling-Hui Zeng, Nicholas R Rensing, Michael Won. Developing Antiepileptogenic Drugs for Acquired Epilepsy: Targeting the Mammalian Target of Rapamycin (mTOR) Pathway. Molecular and cellular pharmacology. vol 1. issue 3. 2021-10-20. PMID:20419051. recent work implicates the mammalian target of rapamycin (mtor) pathway as mediating epileptogenesis in a genetic epilepsy, tuberous sclerosis complex (tsc), and suggests that mtor inhibitors, such as rapamycin, may have antiepileptogenic properties for epilepsy in tsc. 2021-10-20 2023-08-12 Not clear
Maren Schmiester, Anna Dolnik, Uwe Kornak, Berit Pfitzner, Michael Hummel, Denise Treue, Arndt Hartmann, Abbas Agaimy, Veronika Weyerer, Anja Lekaj, Susanne Brakemeier, Robert Peters, Robert Öllinger, Sven Märdian, Lars Bullinger, Jana Käthe Striefler, Anne Flörcke. TFE3 activation in a TSC1-altered malignant PEComa: challenging the dichotomy of the underlying pathogenic mechanisms. The journal of pathology. Clinical research. vol 7. issue 1. 2021-10-13. PMID:33180365. upregulation of mtor signaling due the inactivation of tsc1/2 (tuberous sclerosis 1 and 2) is believed to be a key oncogenic driver in this disease. 2021-10-13 2023-08-13 Not clear